Skip to main contentAI and Advanced
/
ADVENZYMES · NSEMarket ticker unavailable · configure an authorised index feed
AD
NSE · Equity shares · Biotechnology & Drugs-2.80 · -0.97%
Advanced Enzyme Technologies ADVENZYMES
NSE:INR 287.1
BSE:INR 330.7
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for ADVENZYMES
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 289.9
Day rangeINR 282.05 — INR 293.2
52-week rangeINR 251.95 — INR 419
Volume1.79 L
Market cap3,704.17
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)745.76
Net Income (INR Cr)168.72
EPS14.33
Research path: Interpret Advanced Enzyme Technologies's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ADVENZYMESAdvanced Enzyme Technologies1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,838.76 | 1,621.35 | 1,535.46 |
| Accumulated Depreciation Total | -244.61 | -215.14 | -188.08 |
| Cash Equivalents | 56.59 | 66.75 | 71.75 |
| Other Liabilities Total | 5.39 | 1.37 | 0.89 |
| Accrued Expenses | 18.13 | 30.74 | 27.18 |
| Long Term Debt | 7.71 | 9.03 | 6.65 |
| Common Stock Total | 22.38 | 22.38 | 22.37 |
| Other Equity Total | 257.93 | 164.12 | 144.8 |
| Other Current Assets Total | 2.2 | 1.6 | 1.95 |
| Prepaid Expenses | 3.84 | 3.62 | 3.96 |
| Total Assets | 1,838.76 | 1,621.35 | 1,535.46 |
| Current Portof LT Debt/Capital Leases | 9.17 | 7.29 | 6.91 |
| Additional Paid-In Capital | 85.85 | 84.02 | 82.13 |
| Cash | 52.17 | 27.48 | 42 |
| Total Equity | 1,644.2 | 1,433.1 | 1,336.37 |
| Long Term Investments | 0.06 | 0.07 | 0.16 |
| Retained Earnings(Accumulated Deficit) | 1,278.03 | 1,162.58 | 1,087.07 |
| Total Common Shares Outstanding | 11.19 | 11.19 | 11.18 |
| Property/Plant/Equipment Total-Gross | 571.61 | 528.03 | 493.79 |
| Tangible Book Valueper Share Common Eq | 109.7 | 93.61 | 85.2 |
| Goodwill Net | 369.46 | 333.44 | 325.29 |
| Total Liabilities | 194.57 | 188.25 | 199.1 |
| Total Debt | 32.01 | 39.35 | 47.31 |
| Short Term Investments | 598.44 | 500.83 | 434.22 |
| Cashand Short Term Investments | 707.2 | 595.05 | 547.97 |
| Total Receivables Net | 150.82 | 120.49 | 103.42 |
| Notes Payable/Short Term Debt | 11.18 | 11.15 | 17.58 |
| Deferred Income Tax | 31.87 | 33.63 | 34.32 |
| Accounts Receivable-Trade Net | 145.54 | 115.81 | 99.25 |
| Property/Plant/Equipment Total-Net | 327 | 314.63 | 307.27 |
| Minority Interest | 38.93 | 35.57 | 34.71 |
| Total Current Liabilities | 106.72 | 96.76 | 106.36 |
| Total Inventory | 179.52 | 159.1 | 152.44 |
| Accounts Payable | 39.96 | 17.2 | 15.76 |
| Other Currentliabilities Total | 28.28 | 30.38 | 38.92 |
| Total Long Term Debt | 11.66 | 20.92 | 22.82 |
| Intangibles Net | 46.92 | 52.31 | 58.29 |
| Other Long Term Assets Total | 15.82 | 21.54 | 19.89 |
| Note Receivable-Long Term | 35.92 | 19.49 | 14.82 |
| Total Current Assets | 1,043.57 | 879.87 | 809.74 |
| Capital Lease Obligations | 3.95 | 11.89 | 16.16 |
Fundamentals
Valuation and ratios
Valuation
Price to Sale Ratio4.97
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk39.61
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions1
Strong Sell count0
Sell count0
Hold count0
Buy count1
Strong Buy count0
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
Peer data unavailable in the company profile payload.
Shareholding
Ownership
- Promoter
- 43.24%
- FII
- 26.70%
- MF
- 1.82%
- Other
- 28.24%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Advanced Enzyme Technologies Q4 FY26: Robust Profit Surge Masks Margin Volatility Concerns - Markets MojoMarket news · 3 Jun 2026, 2:52 am
Advanced Enzyme Technologies Q4 FY26: Robust Profit Surge Masks Margin Volatility Concerns Markets Mojo
How The Story Around Advanced Enzyme Technologies (NSEI:ADVENZYMES) Is Evolving Without New Analyst Calls - Yahoo FinanceMarket news · 2 Jun 2026, 4:39 am
How The Story Around Advanced Enzyme Technologies (NSEI:ADVENZYMES) Is Evolving Without New Analyst Calls Yahoo Finance
Advanced Enzyme Technologies Ltd is Rated Hold - Markets MojoMarket news · 31 May 2026, 3:21 pm
Advanced Enzyme Technologies Ltd is Rated Hold Markets Mojo
Advanced Enzyme Technologies Annual Secretarial Compliance Report for FY 2026 - InvestyWiseMarket news · 20 May 2026, 6:32 pm
Advanced Enzyme Technologies Annual Secretarial Compliance Report for FY 2026 InvestyWise
Golden Cross Confirmed: Do Advanced Enzyme Technologies Ltd's Other Technical Indicators Agree? - Markets MojoMarket news · 20 May 2026, 12:30 pm
Golden Cross Confirmed: Do Advanced Enzyme Technologies Ltd's Other Technical Indicators Agree? Markets Mojo
Advanced Enzyme PAT Surges 69% to ₹453 Mn in Q4 - scanx.tradeMarket news · 18 May 2026, 12:30 pm
Advanced Enzyme PAT Surges 69% to ₹453 Mn in Q4 scanx.trade
Corporate actions
Events
- board MeetingsQuarterly Results & Buy Back
- annual General MeetingAGM
- dividendRs.1.3500 per share(67.5%)Dividend
- board MeetingsAudited Results & Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Advanced Enzyme Technologies
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Not available
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ADVENZYMES
- BSE Code
- 540025
Questions
Stock FAQ
What is the symbol and ISIN of Advanced Enzyme Technologies?
Advanced Enzyme Technologies has the symbol ADVENZYMES and ISIN - INE837H01020.
What is the current price of Advanced Enzyme Technologies?
Advanced Enzyme Technologies is currently trading at INR 287.10.
What are the year high and year low of Advanced Enzyme Technologies?
Advanced Enzyme Technologies has a year high of INR 419.00 and a year low of INR 251.95.
What is the market capitalization of Advanced Enzyme Technologies?
Advanced Enzyme Technologies has a market capitalization of INR 3,704.17 crore.
What is the P/E ratio of Advanced Enzyme Technologies?
Advanced Enzyme Technologies has a P/E ratio of NA.
What is the dividend yield of Advanced Enzyme Technologies?
Advanced Enzyme Technologies has a dividend yield of NA.
How is the financial performance of Advanced Enzyme Technologies based on revenue, net income, and EPS?
Advanced Enzyme Technologies has revenue of INR 745.76 crore, net income of INR 168.72 crore, and EPS of NA.
What is the book value of Advanced Enzyme Technologies?
Advanced Enzyme Technologies has a book value of NA.
What is the debt-to-equity ratio of Advanced Enzyme Technologies?
Advanced Enzyme Technologies has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Advanced Enzyme Technologies?
Advanced Enzyme Technologies has a price-to-book ratio of NA and a price-to-sales ratio of 4.97.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.